BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38200511)

  • 21. Machine learning-based radiomics strategy for prediction of cell proliferation in non-small cell lung cancer.
    Gu Q; Feng Z; Liang Q; Li M; Deng J; Ma M; Wang W; Liu J; Liu P; Rong P
    Eur J Radiol; 2019 Sep; 118():32-37. PubMed ID: 31439255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy.
    Chang R; Qi S; Wu Y; Yue Y; Zhang X; Qian W
    Cancer Imaging; 2023 Oct; 23(1):101. PubMed ID: 37867196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CT-based radiomics signatures can predict the tumor response of non-small cell lung cancer patients treated with first-line chemotherapy and targeted therapy.
    Yang F; Zhang J; Zhou L; Xia W; Zhang R; Wei H; Feng J; Zhao X; Jian J; Gao X; Yuan S
    Eur Radiol; 2022 Mar; 32(3):1538-1547. PubMed ID: 34564744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
    Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
    Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
    [No Abstract]   [Full Text] [Related]  

  • 27. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-level multi-modality (PET and CT) fusion radiomics: prognostic modeling for non-small cell lung carcinoma.
    Amini M; Nazari M; Shiri I; Hajianfar G; Deevband MR; Abdollahi H; Arabi H; Rahmim A; Zaidi H
    Phys Med Biol; 2021 Oct; 66(20):. PubMed ID: 34544053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prognostic analysis method for non-small cell lung cancer based on the computed tomography radiomics.
    Wang X; Duan H; Li X; Ye X; Huang G; Nie S
    Phys Med Biol; 2020 Feb; 65(4):045006. PubMed ID: 31962301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 32. Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC.
    Bouhamama A; Leporq B; Faraz K; Foy JP; Boussageon M; Pérol M; Ortiz-Cuaran S; Ghiringhelli F; Saintigny P; Beuf O; Pilleul F
    Front Radiol; 2023; 3():1168448. PubMed ID: 37492391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
    Carvalho S; Leijenaar RTH; Troost EGC; van Timmeren JE; Oberije C; van Elmpt W; de Geus-Oei LF; Bussink J; Lambin P
    PLoS One; 2018; 13(3):e0192859. PubMed ID: 29494598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
    Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
    Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
    Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
    Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.
    Vuong D; Bogowicz M; Denzler S; Oliveira C; Foerster R; Amstutz F; Gabryś HS; Unkelbach J; Hillinger S; Thierstein S; Xyrafas A; Peters S; Pless M; Guckenberger M; Tanadini-Lang S
    Med Phys; 2020 Sep; 47(9):4045-4053. PubMed ID: 32395833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
    Tankyevych O; Trousset F; Latappy C; Berraho M; Dutilh J; Tasu JP; Lamour C; Cheze Le Rest C
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CT-based radiomics in predicting pathological response in non-small cell lung cancer patients receiving neoadjuvant immunotherapy.
    Lin Q; Wu HJ; Song QS; Tang YK
    Front Oncol; 2022; 12():937277. PubMed ID: 36267975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
    JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
    Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
    J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.